(TheNewswire)
Sernova to delivercorporate update with focus on value-driving events:
technology acquisition, licensing and research collaboration
LONDON, ONTARIO - TheNewswire - September 24, 2020 - Sernova Corp. (TSXV:SVA)(OTC:SEOVF) (FSE:PSH), a clinical-stage regenerative medicine company,announced today that Dr. Philip Toleikis, President and CEO, willprovide a corporate update as part of the Company Presentations at theupcoming BIO Investor Forum Digital international biotech investorconference from October 13-15, 2000. Dr. Toleikis will also be engagedwith the BIO One-on-One Partnering meetings.
"Amidst the COVID-19 pandemic, we are leveragingthe proliferation of the virtual conference format. This virtualconference will enable us to increase the awareness level amongst anexpanded base of potential investors and partnering prospects aboutSernova's significant advancements, including first-time diabetesclinical trial findings, a technology acquisition for our cell therapytherapeutics platform, and local immune protection technologylicensing and research collaboration arrangements. The BIO One-on-OnePartnering meeting sessions will also enable us to continuediscussions and further evaluate opportunities," said Dr. PhilipToleikis, President and CEO of Sernova.
Sernova's presentation will be available on-demand toattendees of the BIO Investor Forum Digital conference. For moredetails on Sernova's presentation, please visit https://www.bio.org/events/bio-investor-forum-digital/company-presentations .
ABOUT SERNOVA CORP.
Sernova Corp is developing regenerative medicinetherapeutic solutions using a medical device (Cell Pouch(TM)) andimmune protected therapeutic cells/tissues (i.e. human donor cells,corrected human cells, and stem cell-derived cells) to improve thetreatment and quality of life of people with chronic metabolicdiseases such as insulin-dependent diabetes, blood disorders includinghemophilia, and other diseases treated through cellular production ofproteins or hormones missing or in short supply within the body. Formore information, please visit www.sernova.com .
ABOUT SERNOVA'S CELL POUCHSYSTEM
The Cell Pouch, as part of the Cell Pouch System, is anovel, proprietary, scalable, implantable macro-encapsulation devicesolution designed for the long-term survival and function oftherapeutic cells. The device, upon implantation, is designed toincorporate with tissue, forming highly vascularized tissue chambersfor the transplantation and function of therapeutic cells, which thenrelease proteins, hormones, or other factors as required to treatdisease. Sernova is currently conducting a Phase I/II study at theUniversity of Chicago and has demonstrated encouraging early safetyand efficacy indicators. The Cell Pouch, in combination withtherapeutic cells/tissues, has been shown to provide long-term safetyand efficacy in preclinical models of diabetes, hemophilia A and otherindications supporting our therapeutics platform.
For further information contact:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
Forward-Looking Information
This release contains statements that, to the extentthey are not recitations of historical facts, may constitute"forward-looking statements" that involve various risks,uncertainties, and assumptions, including, without limitation,statements regarding the prospects, plans, and objectives of theCompany. Wherever possible, but not always, words such as"expects", "plans", "anticipates","believes", "intends", "estimates","projects", "potential for" and similarexpressions, or that events or conditions "will","would", "may", "could" or"should" occur are used to identify forward-lookingstatements. These statements reflect management's beliefs with respectto future events and are based on information currently available tomanagement on the date such statements were made. Many factors couldcause Sernova's actual results, performances or achievements to not beas anticipated, estimated or intended or to differ materially fromthose expressed or implied by the forward-looking statements containedin this news release. Such factors could include, but are not limitedto, the Company's ability to secure additional financing and licensingarrangements on reasonable terms, or at all; ability to conduct allrequired preclinical and clinical studies for the Company's Cell PouchSystem and/or related technologies, including the timing and resultsof those trials; ability to obtain all necessary regulatory approvals,or on a timely basis; ability to in-license additional complementarytechnologies; ability to execute its business strategy andsuccessfully compete in the market; and the inherent risks associatedwith the development of biotechnology combination products generally.Many of the factors are beyond our control, including those caused by,related to, or impacted by the novel coronavirus pandemic. Investorsshould consult the Company's quarterly and annual filings available onwww.sedar.com for additional information on risks and uncertaintiesrelating to the forward-looking statements. Sernova expresslydisclaims any intention or obligation to update or revise anyforward-looking statements, whether as a result of new information,future events or otherwise.
Copyright (c) 2020 TheNewswire - All rights reserved.